# SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg

> **NCT01227291** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sylentis, S.A.** · enrollment: 30 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** SYL040012

## Key facts

- **NCT ID:** NCT01227291
- **Lead sponsor:** Sylentis, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-03
- **Final completion:** 2012-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227291, "SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01227291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*